Siemens Healthineers' Latest Innovations Contributing to Medical Tech Growth
By MedTech Outlook | Friday, January 04, 2019
Digital Technologies have given significant contributions to the world, especially in the medical sector. With the increased use of telehealth services, electronic medical records (EMR), and mobile technologies such as smart wearables, doctors and patients see the advantages of these new medical technologies. Healthcare technology solutions are evolving in the market with more advancement, and healthcare providers are focusing more on giving the best healthcare services with connected devices and equipment.
Siemens Healthineers [SHL:GR], a leading healthcare organization, enables healthcare providers to boost their value by enabling them to expand precision medicine, transform care delivery, and improve patient experience, all enabling them to digitize healthcare. Approximately five million patients worldwide benefit from the innovative technology solutions that the company offers in the fields of diagnostic and therapeutic imaging, molecular medicine, laboratory diagnostics, and digital health and enterprise services. Siemens Healthineers has now completed 170 years in this market impacting 18000 patients worldwide, and the company continues to innovate and function with more than 48000 colleagues in over 70 countries.
The company has recently obtained 12 Pre-Market Approvals from the FDA for its infectious disease and oncology test menu. This milestone means that Atellica® Solution1, a technology solution by the company designed to address common clinical laboratory challenges, is now supplying laboratories in the United States, with an extensive menu for in vitro diagnostic testing needs of patients on a single laboratory platform.
“These 12 PMA assays, combined with recently released High-Sensitivity Troponin I and Procalcitonin assays, provide a comprehensive menu on the Atellica Solution. Laboratories seeking a broad menu supporting the needs of their clinicians and patients can now find it on the Atellica Solution,” says Deepak Nath, Ph.D., President, Laboratory Diagnostics, Siemens Healthineers. The new Atellica Solution infectious disease tests include HIV2 and HIV 1/O/2 Enhanced(EHIV) and Hepatitis B and C and offer testing options for hepatitis screening, diagnosis, and monitoring to physicians.
Siemens Healthineers continually updates its product and service portfolio in its core diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine. In 2018, the company generated € 13.4 billion in revenue and an operating profit of € 2.3 billion, with around 50,000 employees worldwide. This ensures promising services the company will continue to offer to enable its clients to build provide better care.